Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesConvection-enhanced delivery for the treatment of brain tumors
Expert Review of Neurotherapeutics, 10/21/09
Debinski W et al. – The first Phase III trial for CED–delivered, molecularly targeted cytotoxin in the treatment of recurrent glioblastoma multiforme has been accomplished and demonstrated objective clinical efficacy. The lessons learned from more than a decade of attempts at exploiting CED for brain cancer treatment weigh critically for its future clinical applications. The main issues center around the type of catheters used, number of catheters and their exact placement; pharmacological formulation of drugs, prescreening patients undergoing treatment and monitoring the distribution of drugs in tumors and the tumor–infiltrated brain. It is expected that optimizing CED will make this technology a permanent addition to clinical management of brain malignancies.
Related Articles
Brain Tumor Survivors Speak Out
Journal of Pediatric Oncology Nursing, 10/26/09
Relevance Score: 70%
Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper
Journal of Neuro-Oncology, 10/26/09
Relevance Score: 70%
Endocrine Late Effects in Survivors of Pediatric Brain Tumors
Journal of Pediatric Oncology Nursing, 10/26/09
Relevance Score: 69%
Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors
Annals of the Indian Academy of Neurology, 10/16/09
Relevance Score: 69%
Brain damage from anticancer treatments in adults
Current Opinion in Oncology, 10/13/09
Relevance Score: 68%
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Complete percutaneous treatment of vertebral body tumors causing spinal canal compromise using a transpedicular cavitation, cement augmentation, and radiosurgical technique
Neurosurgical Focus, 12/17/09
Oxaliplatin-induced Lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity
Oncology (Karger), 12/17/09
Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma
Journal of Neuro-Oncology, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor